Cancer, Diffuse large B cell lymphoma
ALLOAllogene TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Cemacabtagene Ansegedleucel (cema-cel) in Cancer, Diffuse large B cell lymphoma. The expected timing is based on the latest available company guidance and may change.
05/13/26:- ALPHA3 MRD data reported. Interim EFS Mid-2027, enrollment End-2027, primary EFS Mid-2028. 07/29/26:- FDA granted RMAT and Fast Track. ALPHA3 Day 45 MRD negativity 58.3% vs 16.7%. 08/12/26:- ALPHA3 interim analysis supported cema-cel. Interim EFS data will be updated Mid-2027; enrollment will complete by year-end 2027.
Verification
Confirm timing and program details against the company announcement or filing.